India, Feb. 16 -- Sanofi (SNY) said a universal respiratory syncytial virus immunization program using Beyfortus or nirsevimab was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study. The data was published in The Lancet Infectious Diseases.
"This universal RSV immunization program with Beyfortus showed decreased RSV-related hospitalizations and outpatient illness burden during the first season, with persistent impact seen on RSV hospitalizations through the second season," said Federico Martinon-Torres, Head of Pediatrics at Santiago University Hospital in Spain, and principal investigator of the NIRSE-GAL...